SCHEMBL1734834

SCHEMBL1734834

c1ccc(CP(C2C3CC4CC(C3)CC2C4)C2C3CC4CC(C3)CC2C4)c(CP(C2C3CC4CC(C3)CC2C4)C2C3CC4CC(C3)CC2C4)c1

nearest known ligand 0.35

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
EPHX2 P34913 5/20 0.32
CXCR3 P49682 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3000347 0.88
SCHEMBL1734019 0.87
SCHEMBL727666 0.85 CYP2D6 (0.44)
SCHEMBL1423105 0.83 SIGMAR1 (0.32)
SCHEMBL726031 0.82 CHRM2 (0.42) CHRM2CHRM4CHRM5EPHX2CXCR3
SCHEMBL14949937 0.82 BACE1 (0.34) CHRM2CHRM4CHRM5
SCHEMBL2145692 0.82 FLT3 (0.33)
SCHEMBL3005857 0.81 FAAH (0.32) EPHX2
SCHEMBL16524443 0.77 ALDH1A1 (0.31)
SCHEMBL28392925 0.77 TAAR1 (0.37) CHRM2CHRM4CHRM5EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794548-B1 A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE LUCITE INT UK LTD (GB) 2019-05-15 EP claimed
US-9382190-B2 Continuous process for the carbonylation of ethylene LUCITE INTERNATIONAL UK LIMITED (GB) 2016-07-05 US claimed
US-20150099896-A1 CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE LUCITE INTERNATIONAL UK LIMITED (GB) 2015-04-09 US claimed
EP-1931471-B1 CONTINUOUS CARBONYLATION PROCESS LUCITE INT UK LTD (GB) 2014-10-01 EP claimed
EP-2007703-B1 METAL COMPLEXES FOR USE IN THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS LUCITE INT UK LTD (GB) 2013-12-18 EP claimed
US-8604236-B2 Catalyst system LUCITE INTERNATIONAL UK LIMITED (GB) 2013-12-10 US claimed
US-20100197958-A1 PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM LUCITE INTERNATIONAL UK LIMITED (GB) 2010-08-05 US claimed
EP-1527038-B1 PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUDS LUCITE INT UK LTD (GB) 2010-03-17 EP claimed
US-20090312561-A1 METAL COMPLEXES LUCITE INTERNATIONAL UK LIMITED (GB) 2009-12-17 US claimed
US-20090216041-A1 Catalyst System LUCITE INTERNATIONAL UK LIMITED (GB) 2009-08-27 US claimed
US-20080051475-A1 Process for the Hydroformylation of Ethylenically Unsaturated Compounds LUCITE INTERNATIONAL UK LIMITED (GB) 2008-02-28 US claimed
EP-1565425-B1 Production process of a lactate ester or acid LUCITE INT UK LTD (GB) 2008-02-20 EP claimed
WO-2024139427-A1 CATALYST SYSTEM AND METHOD FOR CARBONYLATION REACTION 浙江新和成股份有限公司 2024-07-04 WO disclosed
EP-2243549-B1 A CATALYST SYSTEM LUCITE INT UK LTD (GB) 2020-09-02 EP disclosed
EP-2794548-B1 A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE LUCITE INT UK LTD (GB) 2019-05-15 EP disclosed
EP-2513031-B1 A CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE LUCITE INT UK LTD (GB) 2018-08-22 EP disclosed
US-20060106259-A1 Phospha-adamantane(s) catalytic system LUCITE INTERNATIONAL UK LIMITED (GB) 2006-05-18 US disclosed
EP-1651587-A1 PROCESS FOR THE HYDROFORMYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS Lucite International UK Limited (GB) 2006-05-03 EP disclosed
WO-2005079981-A1 A CATALYST SYSTEM LUCITE INTERNATIONAL UK LIMITED (GB) 2005-09-01 WO disclosed
WO-2005003070-A1 PROCESS FOR THE HYDROFORMYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS LUCITE INTERNATIONAL UK LIMITED (GB) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106259-A1 Phospha-adamantane(s) catalytic system ADORA2A, ADORA3, ADGRE5 CHRM2 42/4885CHRM4 89/4885CHRM5 16/4885
US-20150099896-A1 CONTINUOUS PROCESS FOR THE CARBONYLATION OF ETHYLENE SCD, ELOVL6, ALK CHRM2 580/4885CHRM4 309/4885CHRM5 1385/4885
US-20090216041-A1 Catalyst System CBS, SMS, POF1B CHRM2 2878/4885CHRM4 2023/4885CHRM5 2238/4885
US-20080051475-A1 Process for the Hydroformylation of Ethylenically Unsaturated Compounds ETV6, DHPS, ELOVL6 CHRM2 2979/4885CHRM4 2283/4885CHRM5 3688/4885
US-20100197958-A1 PROCESS FOR THE CARBONYLATION OF AN ETHYLENICALLY UNSATURATED COMPOUND AND A CATALYST SYSTEM ALOX5, ACSL5, ELOVL5 CHRM2 123/4885CHRM4 60/4885CHRM5 7/4885
US-20090312561-A1 METAL COMPLEXES MLX, PICALM, AP2M1 CHRM2 34/4885CHRM4 44/4885CHRM5 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.